Compare · BDX vs SRDX
BDX vs SRDX
Side-by-side comparison of Becton Dickinson and Company (BDX) and Surmodics Inc. (SRDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SRDX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 86.4x SRDX ($598.4M).
- BDX has hit the wire 10 times in the past 4 weeks while SRDX has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 7 for SRDX).
- Company
- Becton Dickinson and Company
- Surmodics Inc.
- Price
- -
- -
- Market cap
- $51.69B
- $598.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 7
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Surmodics Inc.
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The Vitro Diagnostics segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest SRDX
- SEC Form 15-12G filed by Surmodics Inc.
- SEC Form EFFECT filed by Surmodics Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Surmodics Inc.
- SVP, Medical Device Coatings Olson Charles W returned 52,278 shares to the company, closing all direct ownership in the company (SEC Form 4)
- VP Finance, Corp. Controller Manders John D. returned 8,155 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Sr. VP of Legal, GC and Sec. Weber Gordon S. returned 21,040 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP, Vascular Interventions Sides Teri Woodwick returned 34,703 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Dantzker David returned 40,183 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Heine Lisa Wipperman returned 13,978 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Knight Susan E returned 37,240 shares to the company, closing all direct ownership in the company (SEC Form 4)